Cabaletta Bio Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
CABA$1.45-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-in Capital | Accumulated Other Comprehensive Income | Accumulated Deficit | TotalStockholders’ Equity | |
| Balance—December 31, 2022 | 29,445,134 | $— | $270,129 | $(47) | $(165,562) | $104,520 |
| Stock-based compensation | — | — | 2,480 | — | — | 2,480 |
| Net unrealized gains on available-for-sale securities | — | — | — | 47 | — | 47 |
| Issuance of common stock in connection with exercise of stock options | 84,264 | — | 458 | — | — | 458 |
| Issuance of common stock upon exercise of pre-funded warrants | 1,811,591 | — | — | — | — | — |
| Net loss | — | — | — | — | (15,854) | (15,854) |
| Balance—March 31, 2023 | 31,340,989 | $— | $273,067 | $— | $(181,416) | $91,651 |
| Stock-based compensation | — | — | 2,803 | — | — | 2,803 |
| Issuance of common stock, net of issuance costs of $6,295 | 8,337,500 | — | 93,755 | — | — | 93,755 |
| Issuance of common stock in connection with exercise of stockoptions | 107,122 | — | 390 | — | — | 390 |
| Issuance of common stock under employee stock purchase plan | 8,071 | — | 32 | — | — | 32 |
| Net unrealized losses on available-for-sale securities | — | — | — | (3) | — | (3) |
| Net loss | — | — | — | — | (14,487) | (14,487) |
| Balance—June 30, 2023 | 39,793,682 | $— | $370,047 | $(3) | $(195,903) | $174,141 |
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | AdditionalPaid-in Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | TotalStockholders’ Equity | |
| Balance—December 31, 2023 | 47,823,232 | $— | $469,396 | $39 | $(233,237) | $236,198 |
| Issuance of common stock, net of issuance costs of $147 | 258,070 | — | 5,746 | — | — | 5,746 |
| Stock-based compensation | — | — | 3,791 | — | — | 3,791 |
| Net unrealized losses on available-for-sale securities | — | — | — | (77) | — | (77) |
| Issuance of common stock in connection with exercise of stock options | 167,813 | — | 1,109 | — | — | 1,109 |
| Net loss | — | — | — | — | (25,047) | (25,047) |
| Balance—March 31, 2024 | 48,249,115 | $— | $480,042 | $(38) | $(258,284) | $221,720 |
| Stock-based compensation | — | — | 5,013 | — | — | 5,013 |
| Issuance of common stock in connection with exercise of stockoptions | 27,407 | — | 250 | — | — | 250 |
| Issuance of common stock under employee stock purchase plan | 14,947 | — | 129 | — | — | 129 |
| Net unrealized gains on available-for-sale securities | — | — | — | 9 | — | 9 |
| Net loss | — | — | — | — | (27,602) | (27,602) |
| Balance—June 30, 2024 | 48,291,469 | $— | $485,434 | $(29) | $(285,886) | $199,519 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.